EGFR and cancer: Given that the anti‐EGFR nanobody 7D12 can bind and block EGFR with all known acquired resistance mutations,[25] our findings suggest that the multivalent Rha‐7D12 conjugate, with its enhanced Fc effector functions and proteolytic resistance, represents a promising modality for overcoming cetuximab resistance in cancer immunotherapy.